IP Library Granted Patent US 9,446,139
Granted Patent B2
US 9,446,139 · App. 11/082,229 · Granted Sep 20, 2016

Polymer-based compositions and conjugates of HIV entry inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,446,139
App. No.
11/082,229
Granted
Sep 20, 2016
Kind
B2
Abstract

Provided herein are water-soluble polymer conjugates and polymer-based compositions of HIV entry inhibitors. Also provided are methods for synthesizing and administering such conjugates and compositions.

Claims (35)

1. An HIV-entry inhibitor-water-soluble polymer conjugate having a structure:

wherein:

EI is an HIV-entry inhibitor that corresponds to T-20 or T-1249,

POLY is a water-soluble, poly(alkylene oxide),

k is selected from 1, 2, and 3,

L is —O— or —NH—C(O)—,

Ar is an aromatic group,

—NH-EI in structure II represents an amino group of the EI,

P is a spacer,

Z is —O— or —NH—,

—O-EI in structure III represents a hydroxyl group of the EI,

and further wherein the poly(alkylene oxide) is covalently attached to the entry inhibitor by a hydrolyzable linkage effective to release the entry inhibitor upon hydrolysis.

2. The conjugate of claim 1 , wherein each poly(alkylene oxide) is a poly(ethylene glycol).

3. The conjugate of claim 2 , wherein each poly(ethylene glycol) is terminally capped with an end-capping moiety selected from the group consisting of hydroxy, alkoxy, substituted alkoxy, alkenoxy, substituted alkenoxy, alkynoxy, substituted alkynoxy, aryloxy and substituted aryloxy.

4. The conjugate of claim 3 , wherein each poly(ethylene glycol) is terminally capped with methoxy.

5. The conjugate of claim 2 , wherein each poly(ethylene glycol) has a molecular weight in a range from about 2,000 Daltons to about 85,000 Daltons.

6. The conjugate of claim 1 , wherein each POLY possesses an architecture selected from the group consisting of linear, branched, and forked.

7. The conjugate of claim 1 , wherein the EI is T-20.

8. The conjugate of claim 1 , wherein the EI is T-1249.

9. The conjugate of claim 7 , having structure II, wherein the T-20 is modified by hydrolyzable covalent attachment of the poly(alkylene oxide) at one or both of Lys-18, and Lys28.

10. The conjugate of claim 9 , wherein the T-20 is further additionally modified by hydrolyzable covalent attachment of the poly(alkylene oxide) at the N-terminus.

11. The conjugate of claim 8 , having structure II, wherein the T-1249 is modified by hydrolyzable covalent attachment of the poly(alklene oxide) at from one to three of amino acid positions selected from Lys7, Lys21, Lys28 and Lys31.

12. The conjugate of claim 1 , where in structure III, P, when taken together with —NH—P—Z—C(O)—, is a residue of a naturally or non-naturally occurring amino acid.

13. The conjugate of claim 1 , where Ar in structure II is an ortho, meta, or para-substituted phenyl group.

14. The conjugate of claim 1 having structure III, wherein P, when taken together with —NH—P—Z—C(O)—, is glyine or alanine.

15. The conjugate of claim 13 , having structure:

where n ranges from 2 to about 3400.

16. The conjugate of claim 1 , wherein k equals 1.

17. A composition comprising a plurality of conjugates of claim 1 , each conjugate comprised within the plurality having structure II and having a value of k from 1-3.

18. A pharmaceutical composition comprising a conjugate of claim 1 and a pharmaceutically acceptable excipient.

19. A method for making an HIV-entry inhibitor water-soluble polymer conjugate having structure H of claim 1 , comprising contacting, under suitable conjugation conditions, an HIV entry inhibitor that is either T-20 or T-1249, with a polymeric reagent having the structure:

where POLY and Ar are as defined in claim 1 , and where FG is a functional group capable of reaction with an amino group of the HIV entry inhibitor to form a hydrolyzable carbamate linkage.

20. A composition comprising a plurality of mono-conjugates of claim 1 , each conjugate comprised within the plurality having structure II, and having the same chemical structure, where the value of k for each conjugate is 1, and the composition comprises at least two different positional isomers.

21. A composition comprising a plurality of conjugates of claim 1 , each conjugate comprised within the plurality having structure III and having a value of k from 1-3.

22. A composition comprising a plurality of mono-conjugates of claim 1 , each conjugate comprised within the plurality having structure III and having the same chemical structure, where the value of k for each conjugate is 1, and the composition comprises at least two different positional isomers.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036866/0700 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
GRANT OF SECURITY INTEREST Recorded Jul 17, 2012
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 028571/0141 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 019763 FRAME 0356. ASSIGNOR(S) HEREBY CONFIRMS THE NAME OF THE ASSIGNEE IS NEKTAR THERAPEUTICS AL, CORPORATION. Recorded Sep 13, 2011
From: BENTLEY, MICHAEL D.; ZHAO, XUAN
To: NEKTAR THERAPEUTICS AL, CORPORATION
Reel/Frame 026894/0505 →
MERGER Recorded Aug 31, 2009
From: NEKTAR THERAPEUTICS AL, CORPORATION
To: NEKTAR THERAPEUTICS
Reel/Frame 023196/0394 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2007
From: BENTLEY, MICHAEL D; ZHAO, XUAN
To: NEKTAR THERAPEUTICS AL
Reel/Frame 019763/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2006
From: BENTLEY, MICHAEL D.; ZHAO, XUAN
To: NEKTAR THERAPEUTICS, AL CORPORATION
Reel/Frame 018689/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2006
From: ZAPPE, HAROLD
To: NEKTAR THERAPEUTICS AL, CORPORATION
Reel/Frame 017818/0238 →